Tearsheet
HRMY Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About HRMY Interactive Breakdown Better Bets vs. HRMY Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Investor Videos Industry Resource Links External Quote Links

Harmony Biosciences (HRMY)

Market Price (7/5/2026): $37.58 | Market Cap: $2.2 BilSector: Health Care | Industry: Biotechnology

Harmony Biosciences (HRMY)

Market Price (7/5/2026): $37.58
Market Cap: $2.2 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.8%, FCF Yield is 16%

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22%

Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 38%

Low stock price volatility
Vol 12M is 42%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.

Weak multi-year price returns
2Y Excs Rtn is -18%, 3Y Excs Rtn is -64%

Key risks
HRMY key risks include [1] its substantial dependence on a single product, Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.8%, FCF Yield is 16%
1 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22%
2 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 21%
3 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 38%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 38%
4 Low stock price volatility
Vol 12M is 42%
5 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies.
6 Weak multi-year price returns
2Y Excs Rtn is -18%, 3Y Excs Rtn is -64%
7 Key risks
HRMY key risks include [1] its substantial dependence on a single product, Show more.

HRMY in ETFs

Weight = HRMY's share of each fund

VTI0.00%
ITOT0.00%
IWM0.05%
IJR0.08%
VB0.02%
AVUV0.22%
IJT0.16%
SLYG0.15%
+10 more covered ETFs

Valuation & Metrics

FYE: 12/31HRMY [1]S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]$899.1 Mil—
FY 2026 Sales$1.0 Bil—
FY 2027 Sales$1.2 Bil—
FY 2026 Sales Growth12.7%—
FY 2027 Sales Growth14.2%8.1%
EARNINGS
LTM Net Income (GAAP) [3]$145.6 Mil—
FY 2026 Net Income (Non-GAAP)$211.6 Mil—
FY 2027 Net Income (Non-GAAP)$257.1 Mil—
FY 2027 Net Income Growth21.5%17.1%
FY 2026 EPS (Non-GAAP)$3.46—
FY 2027 EPS (Non-GAAP)$4.22—
FY 2027 EPS Growth21.7%—
VALUATION
FY 2026 P/S2.13.2
FY 2027 P/S1.9—
FY 2026 P/E10.319.5
FY 2027 P/E8.5—

[1] HRMY forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 7/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).
HRMYS&P 500
REVENUE GROWTHVERY GOOD
Rev LTM ($ Bil)0.9
Rev Chg Q16.6%8.9%
Rev Chg LTM20.7%7.5%
Rev Chg 3Y Avg24.1%5.9%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)0.2
CFO LTM ($ Bil)0.3
Net Inc LTM ($ Bil)0.1
Op Mgn LTM21.1%18.5%
CFO/Rev LTM38.0%21.4%
Net Inc Mgn16.2%13.1%
VALUATIONLOW
P/S2.43.4
P/CFO6.415.5
P/FCF6.420.2
P/E14.925.1
STABILITYVERY GOOD
Debt/Equity0.070.20
Cash/Assets0.500.07

AI Analysis | Feedback

MetricValueDateSource
Average number of patients on WAKIX81009302025Link
New patients on WAKIX in the quarter5009302025Link

Price Chart

No Events

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 7/1/2026

Harmony Biosciences (HRMY) stock has gained about 35% since 3/31/2026 because of the following key factors:

1. Harmony Biosciences reaffirmed its strong full-year 2026 net revenue guidance for WAKIX, projecting between $1.0 billion and $1.04 billion. This reiteration of guidance, despite a Q1 2026 earnings per share miss of 27.63% and revenue falling short of analyst expectations, signals continued confidence in the flagship product's market performance and its trajectory toward blockbuster status.

2. Significant advancements in the pitolisant franchise and pipeline development have bolstered investor outlook. Harmony Biosciences announced positive results from its pivotal bioequivalence study for the pitolisant gastro-resistant (GR) formulation, with an New Drug Application (NDA) filing on track for Q2 2026, targeting a PDUFA date in fiscal Q1 2027. This, along with utility patent applications for pitolisant GR and high-dose pitolisant (HBS-301) potentially extending exclusivity to 2044, supports the company's long-term growth strategy.

Show more
Updated on 7/1/2026

Harmony Biosciences (HRMY) stock has gained about 35% since 3/31/2026 because of the following key factors:

1. Harmony Biosciences reaffirmed its strong full-year 2026 net revenue guidance for WAKIX, projecting between $1.0 billion and $1.04 billion. This reiteration of guidance, despite a Q1 2026 earnings per share miss of 27.63% and revenue falling short of analyst expectations, signals continued confidence in the flagship product's market performance and its trajectory toward blockbuster status.

2. Significant advancements in the pitolisant franchise and pipeline development have bolstered investor outlook. Harmony Biosciences announced positive results from its pivotal bioequivalence study for the pitolisant gastro-resistant (GR) formulation, with an New Drug Application (NDA) filing on track for Q2 2026, targeting a PDUFA date in fiscal Q1 2027. This, along with utility patent applications for pitolisant GR and high-dose pitolisant (HBS-301) potentially extending exclusivity to 2044, supports the company's long-term growth strategy.

3. A prevailing bullish sentiment among analysts and favorable price targets contributed to the stock's positive trend. The consensus analyst rating for HRMY remains a "Buy" or "Strong Buy," with an average price target of $49.50, suggesting a potential upside of 48.74% from the stock's price of $33.28. For example, H.C. Wainwright reiterated a "Buy" rating with a $55.00 price target following the Q1 2026 earnings report, underscoring a positive long-term outlook for the pitolisant lifecycle strategy.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 33.0% change in HRMY stock from 3/31/2026 to 7/4/2026 was primarily driven by a 47.0% change in the company's P/E Multiple.
(LTM values as of)33120267042026Change
Stock Price ($)28.0137.2633.0%
Change Contribution By: 
Total Revenues ($ Mil)8688993.5%
Net Income Margin (%)18.3%16.2%-11.4%
P/E Multiple10.114.847.0%
Shares Outstanding (Mil)5758-1.4%
Cumulative Contribution33.0%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2026 to 7/4/2026
ReturnCorrelation
HRMY33.0% 
Market (SPY)14.5%-7.2%
Sector (XLV)11.7%29.8%

Fundamental Drivers

The -0.4% change in HRMY stock from 12/31/2025 to 7/4/2026 was primarily driven by a -28.0% change in the company's Net Income Margin (%).
(LTM values as of)123120257042026Change
Stock Price ($)37.4237.26-0.4%
Change Contribution By: 
Total Revenues ($ Mil)8268998.9%
Net Income Margin (%)22.5%16.2%-28.0%
P/E Multiple11.614.827.6%
Shares Outstanding (Mil)5858-0.5%
Cumulative Contribution-0.4%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 7/4/2026
ReturnCorrelation
HRMY-0.4% 
Market (SPY)9.5%16.5%
Sector (XLV)6.2%24.2%

Fundamental Drivers

The 17.9% change in HRMY stock from 6/30/2025 to 7/4/2026 was primarily driven by a 24.8% change in the company's P/E Multiple.
(LTM values as of)63020257042026Change
Stock Price ($)31.6037.2617.9%
Change Contribution By: 
Total Revenues ($ Mil)74589920.7%
Net Income Margin (%)20.5%16.2%-21.0%
P/E Multiple11.914.824.8%
Shares Outstanding (Mil)5758-0.9%
Cumulative Contribution17.9%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2025 to 7/4/2026
ReturnCorrelation
HRMY17.9% 
Market (SPY)21.6%16.7%
Sector (XLV)23.1%22.9%

Fundamental Drivers

The 5.9% change in HRMY stock from 6/30/2023 to 7/4/2026 was primarily driven by a 90.6% change in the company's Total Revenues ($ Mil).
(LTM values as of)63020237042026Change
Stock Price ($)35.1937.265.9%
Change Contribution By: 
Total Revenues ($ Mil)47289990.6%
Net Income Margin (%)40.2%16.2%-59.7%
P/E Multiple11.114.833.4%
Shares Outstanding (Mil)60583.3%
Cumulative Contribution5.9%

LTM = Last Twelve Months as of date shown

Market Drivers

6/30/2023 to 7/4/2026
ReturnCorrelation
HRMY5.9% 
Market (SPY)74.0%23.7%
Sector (XLV)29.1%22.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HRMY Return18%29%-41%7%9%-4%-0%
Peers Return-25%30%20%-6%40%34%106%
S&P 500 Return27%-19%24%23%16%9%99%

Monthly Win Rates [3]
HRMY Win Rate42%58%50%58%58%43% 
Peers Win Rate52%58%52%47%60%49% 
S&P 500 Win Rate75%42%67%75%67%43% 

Max Drawdowns [4]
HRMY Max Drawdown-36%-36%-65%-23%-36%-31% 
Peers Max Drawdown-50%-37%-32%-34%-33%-18% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: JAZZ, AXSM, ALKS, NBIX, ACAD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/2/2026 (YTD)

How Low Can It Go

EventHRMYS&P 500
2025 US Tariff Shock
  % Loss-20.9%-18.8%
  % Gain to Breakeven26.4%23.1%
  Time to Breakeven26 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.3%-9.5%
  % Gain to Breakeven89.8%10.5%
  Time to Breakeven299 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-26.0%-24.5%
  % Gain to Breakeven35.2%32.4%
  Time to Breakeven42 days427 days

Compare to JAZZ, AXSM, ALKS, NBIX, ACAD

In The Past

Harmony Biosciences's stock fell -20.9% during the 2025 US Tariff Shock. Such a loss loss requires a 26.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventHRMYS&P 500
2025 US Tariff Shock
  % Loss-20.9%-18.8%
  % Gain to Breakeven26.4%23.1%
  Time to Breakeven26 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.3%-9.5%
  % Gain to Breakeven89.8%10.5%
  Time to Breakeven299 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-26.0%-24.5%
  % Gain to Breakeven35.2%32.4%
  Time to Breakeven42 days427 days

Compare to JAZZ, AXSM, ALKS, NBIX, ACAD

In The Past

Harmony Biosciences's stock fell -20.9% during the 2025 US Tariff Shock. Such a loss loss requires a 26.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Harmony Biosciences (HRMY)

```html

Harmony Biosciences (HRMY) is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders in the United States. The company, incorporated in 2017 and based in Plymouth Meeting, Pennsylvania, aims to address specific medical needs within this specialized therapeutic area.

The company's primary product is WAKIX (pitolisant), a medication specifically approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Harmony Biosciences' main customers are adult patients in the U.S. diagnosed with narcolepsy who experience this particular symptom, positioning the company as a key provider of treatments for this rare neurological condition.

```

AI Analysis | Feedback

Harmony Biosciences (HRMY) can be described as:

  • Jazz Pharmaceuticals, but primarily focused on its narcolepsy drug WAKIX.
  • Vertex Pharmaceuticals, but for rare neurological sleep disorders.

AI Analysis | Feedback

  • WAKIX: A medication used for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

AI Analysis | Feedback

Harmony Biosciences (HRMY), as a commercial-stage pharmaceutical company, sells its medication WAKIX through the established pharmaceutical distribution channels in the United States. Therefore, its major customers are typically large pharmaceutical wholesalers and distributors, who then supply pharmacies and healthcare providers.

The major customers of Harmony Biosciences are most likely the major pharmaceutical wholesalers in the United States. These include:

  • AmerisourceBergen Corporation (ABC)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)

These companies purchase medications in bulk from manufacturers like Harmony Biosciences and distribute them to retail pharmacies, hospital pharmacies, and other healthcare facilities across the country, which then dispense the medication to individual patients based on prescriptions.

AI Analysis | Feedback

  • Flamma S.p.A.
  • Alcami Corporation

AI Analysis | Feedback

Jeffrey M. Dayno, President and Chief Executive Officer

Dr. Jeffrey M. Dayno assumed the role of President and Chief Executive Officer of Harmony Biosciences in April 2023, having previously served as Interim CEO from January to April 2023. He initially joined Harmony Biosciences as Chief Medical Officer and Executive Vice President in November 2017, the year the company was founded. With over 25 years of experience in the pharmaceutical industry and a background as a practicing neurologist, Dr. Dayno has held leadership positions at various pharmaceutical companies, including Merck & Co., Cephalon, Egalet Corporation (Zyla Life Sciences), and ViroPharma (which was acquired by Shire). He has been instrumental in multiple NDA approvals and product launches throughout his career, and at Harmony, he played a critical role in the FDA approval of WAKIX. Dr. Dayno currently serves on the board of Emalex Biosciences and previously served on the board of Atrin Pharmaceuticals.

Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer

Sandip Kapadia was appointed Chief Financial Officer of Harmony Biosciences effective March 29, 2021. He possesses over 25 years of experience in the life sciences industry, offering strategic financial oversight to companies in both the United States and Europe. Before joining Harmony Biosciences, Mr. Kapadia served as the Chief Financial Officer at Intercept, where he was responsible for leading finance operations, supporting commercialization efforts, executing financial and capital strategies, and raising over $700 million in various financings. Prior to Intercept, he spent a significant portion of his career at Novartis and its affiliates, including serving as Chief Financial Officer of North America at Sandoz, Novartis's generic division. Mr. Kapadia is a Certified Public Accountant and holds an MBA from Rutgers University and a BBA from Montclair State University. He is also a board member of Passage Bio, Inc., Molecular Partners AG, and VectivBio Holding AG.

Dr. Kumar Budur, Executive Vice President, Chief Medical and Scientific Officer

Dr. Kumar Budur serves as the Executive Vice President, Chief Medical and Scientific Officer at Harmony Biosciences, playing a key role in the company's research, development, and medical affairs.

Andrew Serafin, Chief Strategy Officer

Andrew Serafin holds the position of Chief Strategy Officer at Harmony Biosciences, contributing to the company's strategic planning and initiatives.

Adam Zaeske, Chief Commercial Officer

Adam Zaeske is the Chief Commercial Officer at Harmony Biosciences, overseeing the company's commercial operations and strategies.

AI Analysis | Feedback

Here are the key risks to Harmony Biosciences:
  1. Patent Litigation and Potential for Early Generic Competition for WAKIX: Harmony Biosciences faces significant risk from ongoing intellectual property litigation concerning its primary drug, WAKIX. Analysts have downgraded the company's stock due to concerns about a potential unfavorable ruling in an intellectual property case, which could allow generic versions of WAKIX to enter the market much earlier than anticipated, possibly as soon as this year instead of 2030. This would severely impact Harmony's main revenue source.
  2. High Reliance on a Single Commercial Product (WAKIX) and Pipeline Development Challenges: The company is heavily reliant on WAKIX for its revenue, making it vulnerable to any issues affecting this product. Harmony's efforts to diversify its product portfolio have faced setbacks, including the failure of a key pipeline candidate, ZYN-002, in its Phase 3 RECONNECT trial for Fragile X Syndrome. Such pipeline failures increase the company's dependence on WAKIX and limit future growth prospects.
  3. Competitive Market and Drug Pricing Pressures: While WAKIX offers a unique mechanism of action, it operates in a competitive market for narcolepsy treatments. Additionally, Harmony Biosciences, like other pharmaceutical companies, is subject to pressures on US drug prices, which could negatively impact the profitability and market position of WAKIX.

AI Analysis | Feedback

Competition from Avadel Pharmaceuticals' Lumryz, an extended-release sodium oxybate product for narcolepsy approved by the FDA in May 2023. Its once-nightly dosing offers a potential convenience advantage over existing treatments, increasing competition in the narcolepsy market.
The ongoing development of novel orexin receptor agonists by various pharmaceutical companies. These drugs, while some specific programs have faced setbacks, aim to address the underlying pathology of narcolepsy type 1 and could offer more effective or disease-modifying treatments than symptomatic therapies like WAKIX if successfully brought to market.

AI Analysis | Feedback

Harmony Biosciences' main product, WAKIX, addresses the market of patients diagnosed with narcolepsy in the United States.

The addressable market for WAKIX in the U.S. is estimated to be approximately 80,000 diagnosed patients with narcolepsy. Harmony Biosciences has stated that this represents a "large market opportunity" for WAKIX.

The company is guiding WAKIX net revenue to exceed $1 billion, reaching between $1 billion and $1.04 billion, in 2026, indicating this as their targeted opportunity within the narcolepsy market. The overall narcolepsy therapeutics market in the United States was approximately $1.19 billion in 2023 and is projected to reach $1.87 billion by 2030.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Harmony Biosciences (HRMY)

Over the next 2-3 years, Harmony Biosciences (HRMY) is expected to drive future revenue growth through several key initiatives, primarily centered around its flagship product WAKIX and a robust pipeline expansion:

  1. Continued Growth and Patient Adoption of WAKIX in Narcolepsy: Harmony Biosciences anticipates sustained revenue growth from its commercial-stage product, WAKIX, for excessive daytime sleepiness and cataplexy in adult patients with narcolepsy. The company has consistently reported strong demand for WAKIX, with an increase in average patients, and has provided guidance for WAKIX net revenue to reach blockbuster status of $1 billion to $1.04 billion in 2026. This growth is driven by WAKIX's broad clinical utility and ongoing commercial execution.
  2. Expansion of WAKIX Label into New Indications and Patient Populations: Harmony Biosciences is pursuing label expansions for WAKIX to address a broader patient base. A significant driver is the recent FDA approval of WAKIX for the treatment of cataplexy in pediatric narcolepsy patients aged six years and older, which supports pediatric exclusivity and market expansion. Additionally, the company is evaluating pitolisant (WAKIX's active ingredient) for other neurological disorders, including a planned sNDA submission for idiopathic hypersomnia and ongoing Phase 3 trials for pitolisant in Prader-Willi syndrome with topline data expected in the second half of 2026.
  3. Launch of Next-Generation Pitolisant Formulations: The company is advancing new formulations of pitolisant, including Pitolisant GR (gastro-resistant) and Pitolisant HD (high dose). An NDA submission for Pitolisant GR is on track for Q2 2026, with a target PDUFA date in Q1 2027. Pitolisant HD is currently in Phase 3 registrational clinical trials for narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (ONSTRIDE 2), with topline data anticipated in 2027 and potential PDUFA dates in 2028. These next-gen formulations are designed to enhance patient adherence and efficacy, extending the pitolisant franchise into the 2040s and expanding its utility for differentiated indications like fatigue in narcolepsy and sleep inertia in idiopathic hypersomnia.
  4. Advancement and Potential Commercialization of Late-Stage Pipeline Assets: Harmony Biosciences has a robust late-stage pipeline beyond pitolisant, with five ongoing Phase 3 registrational clinical trials across five distinct CNS indications. This includes BP1.15205, a potential best-in-class Orexin-2 agonist, which is currently in a Phase 1 trial with clinical data expected in mid-2026. The company is making strategic investments in research and development to advance these pipeline assets, which are expected to diversify revenue streams beyond WAKIX and contribute to long-term value creation.

AI Analysis | Feedback

Share Repurchases

  • Harmony Biosciences' Board of Directors authorized a $200 million equity buyback program on October 31, 2023.
  • Prior to this, a $125 million share repurchase program was announced on August 1, 2023, reflecting confidence in the company's financial health and growth potential.
  • As of March 31, 2025, the company had repurchased 1,814,653 shares for approximately $49.99 million under the October 31, 2023 buyback plan.

Share Issuance

  • On October 29, 2024, an underwritten public offering of up to 8,000,000 shares of Harmony Biosciences' common stock was commenced by selling shareholders (Marshman Fund Trust II and Valor IV Pharma Holdings, LLC). The company itself did not offer any shares and received no proceeds from this offering.

Inbound Investments

  • Zuckerman Investment Group LLC acquired a new stake of 123,255 shares in Harmony Biosciences, valued at approximately $3.40 million, during the third quarter (prior to March 2026).
  • Institutional investors and hedge funds collectively own approximately 86.23% of the company's stock.

Outbound Investments

  • Harmony Biosciences' strategy includes deploying capital for business development to expand its pipeline and commercial portfolio.
  • In Q2 2025, operating expenses included $42.6 million in in-process research and development (IPR&D) charges from Q2 2024 related to a sublicensing agreement with Bioprojet for an orexin-2 agonist compound and the acquisition of Epygenix.
  • This was partially offset by a $15.0 million IPR&D charge for an upfront fee from the 2025 CiRC Agreement.

Capital Expenditures

  • Harmony Biosciences' capital expenditures have been consistently low, with $0.17 million in 2025, $0.30 million in 2024, $0.00 million in 2023, and $0.15 million in 2022.
  • In Q4 2025, the company invested $107K in capital expenditures, primarily funding long-term assets and infrastructure.
  • The company's overall investment focus includes advancing its late-stage pipeline and supporting the commercialization of WAKIX.

Better Bets vs. Harmony Biosciences (HRMY)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for HRMY: 24.1% | 2.4x)

OSCR (42.9% | 0.7x)
Oscar Health
ALHC (40.9% | 1.1x)
Alignment Healthcare
CLOV (66.9% | 1.2x)
Clover Health Investments
ASTH (43.6% | 0.7x)
Astrana Health
SRPT (33.6% | 0.9x)
Sarepta Therapeutics

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HRMY: 24.1% | 11.4x)

HALO (29.1% | 11.1x)
Halozyme Therapeutics
ADMA (43.0% | 10.2x)
ADMA Biologics
NUTX (71.3% | 5.0x)
Nutex Health
ABUS (926.1% | 6.1x)
Arbutus Biopharma
ESPR (86.0% | 10.5x)
Esperion Therapeutics

Higher Rev Chg LTM (Value for HRMY: 20.7%)

ALNY (82.6%)
Alnylam Pharmaceuticals
LLY (47.4%)
Eli Lilly
NTRA (36.6%)
Natera
WAT (26.4%)
Waters
ISRG (21.4%)
Intuitive Surgical

Higher Rev Chg 3Y Avg (Value for HRMY: 24.1%)

ALNY (58.3%)
Alnylam Pharmaceuticals
INSM (52.8%)
Insmed
NTRA (42.5%)
Natera
LLY (37.9%)
Eli Lilly
GH (31.0%)
Guardant Health

Higher Op Mgn LTM (Value for HRMY: 21.1%)

LLY (47.3%)
Eli Lilly
GILD (40.0%)
Gilead Sciences
ABBV (33.2%)
AbbVie
AMGN (28.4%)
Amgen
JNJ (26.8%)
Johnson & Johnson

Higher CFO/Rev LTM (Value for HRMY: 38.0%)

RPRX (107.0%)
Royalty Pharma
KRYS (60.0%)
Krystal Biotech
VEEV (50.2%)
Veeva Systems
UTHR (49.3%)
United Therapeutics
EXEL (38.9%)
Exelixis

Higher FCF/Rev LTM (Value for HRMY: 38.0%)

RPRX (107.0%)
Royalty Pharma
KRYS (56.9%)
Krystal Biotech
VEEV (50.2%)
Veeva Systems
LGND (41.5%)
Ligand Pharmaceuticals
EXEL (38.1%)
Exelixis

Higher Total Yield (Value for HRMY: 6.8%)

PFE (12.5%)
Pfizer
BMY (10.4%)
Bristol-Myers Squibb
GILD (8.1%)
Gilead Sciences
MDT (7.9%)
Medtronic
ELV (7.4%)
Elevance Health

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for HRMY: 24.1% | 2.4x)

APO (41.0% | 2.2x)
Apollo Global Management
CVNA (24.1% | 2.2x)
Carvana
SLF (24.1% | 1.2x)
Sun Life Financial
LVS (44.9% | 2.3x)
Las Vegas Sands
SW (58.2% | 0.8x)
Smurfit WestRock

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for HRMY: 24.1% | 11.4x)

NEM (30.0% | 7.8x)
Newmont
AEM (32.5% | 10.0x)
Agnico Eagle Mines
APO (41.0% | 9.4x)
Apollo Global Management
AU (40.8% | 8.1x)
Anglogold Ashanti
IBKR (28.2% | 4.5x)
Interactive Brokers

Higher Rev Chg LTM (Value for HRMY: 20.7%)

MU (85.5%)
Micron Technology
NVDA (70.7%)
NVIDIA
AMD (35.0%)
Advanced Micro Devices
AVGO (32.3%)
Broadcom
META (26.2%)
Meta Platforms

Higher Rev Chg 3Y Avg (Value for HRMY: 24.1%)

NVDA (121.7%)
NVIDIA
MU (45.3%)
Micron Technology
PLTR (39.6%)
Palantir Technologies
SNDK (35.6%)
SanDisk
AVGO (29.3%)
Broadcom

Higher Op Mgn LTM (Value for HRMY: 21.1%)

NVDA (64.0%)
NVIDIA
MSFT (46.8%)
Microsoft
AVGO (44.1%)
Broadcom
GOOGL (32.7%)
Alphabet
AAPL (32.6%)
Apple

Higher CFO/Rev LTM (Value for HRMY: 38.0%)

META (57.7%)
Meta Platforms
MSFT (53.5%)
Microsoft
NVDA (49.6%)
NVIDIA
AVGO (44.6%)
Broadcom
GOOGL (41.3%)
Alphabet

Higher FCF/Rev LTM (Value for HRMY: 38.0%)

MA (50.3%)
Mastercard
V (49.2%)
Visa
BAC (48.8%)
Bank of America
NVDA (47.0%)
NVIDIA
AVGO (43.4%)
Broadcom

Higher Total Yield (Value for HRMY: 6.8%)

RY (7.8%)
Royal Bank of Canada
BAC (7.4%)
Bank of America
XOM (7.4%)
Exxon Mobil
CVX (7.3%)
Chevron
KO (6.8%)
Coca-Cola

Best Bets in Health Care

What You Pay

P/EBIT (Value for HRMY: 10.2x)

RPRX (14.9x)
Royalty Pharma
VEEV (32.9x)
Veeva Systems
DOCS (18.8x)
Doximity
HALO (18.0x)
Halozyme Therapeutics
CPRX (14.4x)
Catalyst Pharmaceuticals
HRMY (10.2x)
Harmony Biosciences
NBIX (21.9x)
Neurocrine Biosciences
REGN (13.1x)
Regeneron Pharmaceuticals
ZTS (8.9x)
Zoetis
PBH (7.8x)
Prestige Consumer Healthcare

P/E (Value for HRMY: 14.8x)

RPRX (30.5x)
Royalty Pharma
VEEV (33.4x)
Veeva Systems
DOCS (20.6x)
Doximity
HALO (26.9x)
Halozyme Therapeutics
CPRX (17.4x)
Catalyst Pharmaceuticals
HRMY (14.8x)
Harmony Biosciences
NBIX (26.2x)
Neurocrine Biosciences
REGN (15.4x)
Regeneron Pharmaceuticals
ZTS (11.9x)
Zoetis
PBH (12.3x)
Prestige Consumer Healthcare
What You Get

Rev Chg 3Y Avg (Value for HRMY: 24.1%)

RPRX (1.3%)
Royalty Pharma
VEEV (15.1%)
Veeva Systems
DOCS (15.5%)
Doximity
HALO (29.1%)
Halozyme Therapeutics
CPRX (34.0%)
Catalyst Pharmaceuticals
HRMY (24.1%)
Harmony Biosciences
NBIX (24.8%)
Neurocrine Biosciences
REGN (6.4%)
Regeneron Pharmaceuticals
ZTS (5.5%)
Zoetis
PBH (-1.1%)
Prestige Consumer Healthcare

Rev Chg LTM (Value for HRMY: 20.7%)

RPRX (7.8%)
Royalty Pharma
VEEV (16.2%)
Veeva Systems
DOCS (13.1%)
Doximity
HALO (39.1%)
Halozyme Therapeutics
CPRX (11.7%)
Catalyst Pharmaceuticals
HRMY (20.7%)
Harmony Biosciences
NBIX (28.6%)
Neurocrine Biosciences
REGN (5.9%)
Regeneron Pharmaceuticals
ZTS (2.6%)
Zoetis
PBH (-4.3%)
Prestige Consumer Healthcare

Rev Chg Q (Value for HRMY: 16.6%)

RPRX (11.0%)
Royalty Pharma
VEEV (16.3%)
Veeva Systems
DOCS (5.1%)
Doximity
HALO (42.2%)
Halozyme Therapeutics
CPRX (5.6%)
Catalyst Pharmaceuticals
HRMY (16.6%)
Harmony Biosciences
NBIX (42.2%)
Neurocrine Biosciences
REGN (19.0%)
Regeneron Pharmaceuticals
ZTS (2.9%)
Zoetis
PBH (-5.0%)
Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for HRMY: 33.8%)

RPRX (114.4%)
Royalty Pharma
VEEV (46.4%)
Veeva Systems
DOCS (44.5%)
Doximity
HALO (39.9%)
Halozyme Therapeutics
CPRX (34.9%)
Catalyst Pharmaceuticals
HRMY (33.8%)
Harmony Biosciences
NBIX (26.0%)
Neurocrine Biosciences
REGN (25.5%)
Regeneron Pharmaceuticals
ZTS (22.4%)
Zoetis
PBH (21.8%)
Prestige Consumer Healthcare
[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

Recent Active Movers

Top Gainers

TickerCompanyCategory1W RtnYTD Rtn
NASATema Space Innovators ETFEquity10.4%15.9%
IGViShares Expanded Tech-Software Sector...Equity10.4%-11.5%
ETHAiShares Ethereum Trust ETFCryptocurrency9.5%-42.7%
XOVREntrepreneurShares Series Trust ERSha...Equity7.9%4.3%
MISLFirst Trust Indxx Aerospace & Defense...Equity7.1%9.5%
ARKWARK Next Generation Internet ETFEquity7.0%-1.7%
MAGSRoundhill Magnificent Seven ETFEquity6.6%-1.3%
IBBiShares Biotechnology ETFEquity6.5%16.0%
PALLETFS Physical Palladium SharesCommodity6.5%-21.2%
ARKKARK Innovation ETFEquity6.2%5.6%

Top Losers

TickerCompanyCategory1W RtnYTD Rtn
EWYiShares MSCI South Korea ETFEquity-12.1%85.3%
SOXQInvesco PHLX Semiconductor ETFEquity-9.6%78.2%
SOXXiShares Semiconductor ETFEquity-9.4%88.2%
SMHVanEck Semiconductor ETFEquity-7.0%64.5%
MTUMiShares MSCI USA Momentum Factor ETFEquity-6.7%26.6%
VLUEiShares MSCI USA Value Factor ETFEquity-5.7%41.7%
SPMOInvesco S&P 500 Momentum ETFEquity-5.5%26.8%
USOUnited States Oil Fund LPCommodity-4.9%50.3%
ASHRXtrackers Harvest CSI 300 China A-Sha...Equity-4.2%7.0%
EEMiShares MSCI Emerging Markets ETFEquity-3.3%20.1%

Top Gainers

Top Losers

TickerCompanyCategory1M RtnYTD Rtn
USOUnited States Oil Fund LPCommodity-24.3%50.3%
NASATema Space Innovators ETFEquity-22.7%15.9%
SLViShares Silver TrustCommodity-19.1%-14.6%
URAGlobal X Uranium ETFEquity-19.1%1.2%
ICLNiShares Global Clean Energy ETFEquity-17.2%19.7%
EWYiShares MSCI South Korea ETFEquity-16.0%85.3%
PPLTETFS Physical Platinum SharesCommodity-16.0%-21.0%
COMTiShares GSCI Commodity Dynamic Roll S...Commodity-12.5%21.3%
FXIiShares China Large-Cap ETFEquity-12.2%-16.7%
RINGiShares MSCI Global Gold Miners ETFEquity-11.8%-8.8%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.ACADIA P. 
Mkt Price37.26243.47244.3154.58174.2625.97114.42
Mkt Cap2.215.112.59.117.54.410.8
Rev LTM8994,4397081,5623,1021,0951,329
Op Inc LTM190910-17719279981191
FCF LTM3421,144-71222829118282
FCF 3Y Avg2571,205-12836664577311
CFO LTM3421,334-71256864123299
CFO 3Y Avg2581,310-127406680112332

Growth & Margins

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.ACADIA P. 
Rev Chg LTM20.7%9.2%63.9%3.2%28.6%9.9%15.3%
Rev Chg 3Y Avg24.1%5.9%69.9%15.0%24.8%29.6%24.4%
Rev Chg Q16.6%19.1%57.4%28.2%42.2%9.7%23.6%
QoQ Delta Rev Chg LTM3.5%4.0%10.9%5.9%8.5%2.2%4.9%
Op Inc Chg LTM-2.8%53.1%26.2%-50.9%59.3%-8.4%11.7%
Op Inc Chg 3Y Avg15.3%20.3%-13.6%1,583.6%45.5%705.3%32.9%
Op Mgn LTM21.1%20.5%-24.9%12.3%25.7%7.4%16.4%
Op Mgn 3Y Avg26.7%16.5%-59.3%21.8%23.4%5.2%19.1%
QoQ Delta Op Mgn LTM-2.9%8.4%1.6%-4.9%3.5%-2.4%-0.4%
CFO/Rev LTM38.0%30.1%-10.0%16.4%27.8%11.3%22.1%
CFO/Rev 3Y Avg33.9%31.8%-38.0%25.4%27.5%11.4%26.4%
FCF/Rev LTM38.0%25.8%-10.0%14.2%26.7%10.7%20.0%
FCF/Rev 3Y Avg33.8%29.3%-38.2%22.9%26.0%7.8%24.5%

Valuation

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.ACADIA P. 
Mkt Cap2.215.112.59.117.54.410.8
P/S2.43.417.75.85.64.04.8
P/Op Inc11.416.6-70.947.321.954.719.2
P/EBIT10.2-400.8-68.238.221.954.716.1
P/E14.8511.0-66.459.426.211.820.5
P/CFO6.311.3-176.835.420.335.915.8
Total Yield6.8%0.2%-1.5%1.7%3.8%8.5%2.8%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg14.5%14.2%-2.7%7.1%5.1%2.3%6.1%
D/E0.10.40.00.20.00.00.0
Net D/E-0.20.2-0.00.1-0.1-0.2-0.0

Returns

HRMYJAZZAXSMALKSNBIXACADMedian
NameHarmony .Jazz Pha.Axsome T.Alkermes Neurocri.ACADIA P. 
1M Rtn13.0%1.4%5.5%25.8%4.1%19.6%9.3%
3M Rtn34.3%30.2%45.0%56.7%32.4%17.0%33.4%
6M Rtn-0.3%40.6%36.7%93.1%23.9%-1.2%30.3%
12M Rtn16.0%121.5%135.1%88.2%34.7%22.3%61.4%
3Y Rtn8.8%96.9%235.7%95.1%84.3%7.5%89.7%
1M Excs Rtn22.2%9.3%11.6%33.8%14.2%26.0%18.2%
3M Excs Rtn19.5%15.5%28.4%41.9%17.6%2.5%18.6%
6M Excs Rtn-9.5%34.0%55.7%87.7%15.1%-11.2%24.6%
12M Excs Rtn-4.4%101.7%116.5%67.6%15.4%0.8%41.5%
3Y Excs Rtn-64.1%26.5%122.1%7.0%13.1%-63.7%10.1%

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #		Brand
Name		Generic
Name		Dosage
Form		FDA
Approval		3M
Rtn		6M
Rtn		1Y
Rtn		2Y
Rtn		Total
Rtn
NDA211150  WAKIXpitolisant hydrochloridetablet8142019     
 Collapse to Preview
Post-Approval Fwd Returns
FDA
App #		Brand
Name		Generic
Name		Dosage
Form		FDA
Approval		3M
Rtn		6M
Rtn		1Y
Rtn		2Y
Rtn		Total
Rtn
NDA211150  WAKIXpitolisant hydrochloridetablet8142019     

Financials

$ Mil | FY: 12/312026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End3/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/2023
Filing Date5/7/20262/24/202611/4/20258/5/20255/6/20252/25/202510/29/20248/6/20244/30/20242/22/202410/31/20238/1/2023
Key Financials Quarterly            
Total Revenue215244239200185201186173155168160134
Ebitda495277596766723262516556
Operating Income373965485656622152406547
Net Income322251404649461238273834
EPS0.560.390.880.690.790.870.810.200.680.460.640.57
Key Financials TTM            
Total Revenue TTM899868826773745715682656618582542499
Ebitda TTM237255270265238233218210234222228181
Operating Income TTM190208226222195191175178204192199147
Net Income TTM146159186181153145123115138129151200
Growth Rates Quarterly            
Total Revenue Growth16.6%21.1%28.7%16.0%19.5%19.5%16.1%28.8%29.8%31.3%36.7%25.4%
EBITDA Growth-27.0%-22.0%6.3%84.3%7.3%31.1%11.6%-43.0%26.0%-11.0%260.4%43.8%
Operating Income Growth-33.7%-30.8%6.1%125.6%8.1%38.6%-4.3%-54.5%28.7%-15.6%442.0%41.6%
Net Income Growth-28.7%-54.6%10.4%243.2%18.9%85.9%19.8%-66.2%30.0%-45.2%-56.3%45.8%
Margins Quarterly            
EBITDA Margin22.7%21.2%32.2%29.6%36.3%33.0%39.0%18.6%40.4%30.1%40.5%42.0%
Operating Income Margin17.3%15.8%27.3%24.0%30.4%27.7%33.2%12.4%33.7%23.9%40.3%34.9%
Net Income Margin15.1%9.2%21.2%19.8%24.7%24.6%24.8%6.7%24.8%15.8%24.0%25.6%
Cash & Debt            
Total Cash641775673565507467410347372353371371
Total Debt159164169172176179183186190194197191
Net Debt / (Cash)-482-612-504-393-331-288-228-160-182-160-174-179
Cash Flows Quarterly            
FCF from Operations28126109793476714331776337
Cash Flows TTM            
FCF from Operations TTM342348298259223220221214208219169162
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-050-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC52.0%87.1%102.5%52.8%52.5%53.2%43.9%9.7%35.2%23.9%40.1%28.4%
Return on Invested Capital (ROIC) TTM            
ROIC TTM59.5%157.5%94.4%61.0%44.2%39.2%29.4%26.3%34.2%31.7%35.4%28.6%

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Net product revenue868715582438305
Total868715582438305


Price Behavior

Price Behavior
Market Price$37.26 
Market Cap ($ Bil)2.2 
First Trading Date08/19/2020 
Distance from 52W High-8.0% 
   50 Days200 Days
DMA Price$33.22$38.09
DMA Trenddownup
Distance from DMA12.2%-2.2%
 3M1YR
Volatility36.6%42.4%
Downside Capture-170.3777.28
Upside Capture18.4276.86
Correlation (SPY)-4.6%17.0%
HRMY Betas & Captures as of 6/30/2026

 1M2M3M6M1Y3Y
Beta-0.47-0.240.030.510.560.75
Up Beta-0.180.381.080.860.610.58
Down Beta1.180.470.020.580.040.54
Up Capture-28%-3%23%22%66%69%
Bmk +ve Days11244067140429
Stock +ve Days11203259124362
Down Capture-198%-147%-187%48%83%102%
Bmk -ve Days10172358112321
Stock -ve Days10213164123379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with HRMY
HRMY15.9%42.3%0.47-
Sector ETF (XLV)21.4%15.6%1.0522.8%
Equity (SPY)21.7%12.5%1.2916.8%
Gold (GLD)23.1%27.7%0.73-5.7%
Commodities (DBC)21.3%18.6%0.90-11.6%
Real Estate (VNQ)13.6%13.8%0.6819.7%
Bitcoin (BTCUSD)-42.0%42.7%-1.159.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with HRMY
HRMY4.3%50.1%0.27-
Sector ETF (XLV)7.2%14.9%0.3028.4%
Equity (SPY)13.3%17.1%0.6027.5%
Gold (GLD)17.9%18.3%0.79-3.3%
Commodities (DBC)6.9%19.5%0.25-0.8%
Real Estate (VNQ)3.1%18.9%0.0625.4%
Bitcoin (BTCUSD)12.2%53.8%0.4114.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with HRMY
HRMY0.0%52.3%0.21-
Sector ETF (XLV)10.6%16.6%0.5226.4%
Equity (SPY)15.4%18.0%0.7326.3%
Gold (GLD)12.1%16.1%0.61-3.3%
Commodities (DBC)5.7%18.0%0.250.2%
Real Estate (VNQ)5.5%20.7%0.2323.4%
Bitcoin (BTCUSD)59.0%66.2%0.9911.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date6152026
Short Interest: Shares Quantity4.6 Mil
Short Interest: % Change Since 5312026-21.8%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest5.2 days
Basic Shares Quantity57.8 Mil
Short % of Basic Shares8.0%

Returns Analyses

Earnings Returns History

Updated 6/10/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/7/2026-4.1%-5.9%-1.8%
2/24/20264.9%7.6%0.9%
11/4/20254.7%8.5%30.4%
8/5/2025-1.7%-2.1%5.6%
5/6/20257.0%19.0%17.4%
2/25/20258.2%-5.9%-3.5%
10/29/202416.1%-7.6%-2.6%
8/6/20246.2%8.1%16.6%
...
SUMMARY STATS   
# Positive141413
# Negative9910
Median Positive5.9%9.1%16.6%
Median Negative-4.1%-5.9%-4.3%
Max Positive19.4%26.5%49.2%
Max Negative-17.6%-25.6%-12.0%
 Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/7/2026-4.1%-5.9%-1.8%
2/24/20264.9%7.6%0.9%
11/4/20254.7%8.5%30.4%
8/5/2025-1.7%-2.1%5.6%
5/6/20257.0%19.0%17.4%
2/25/20258.2%-5.9%-3.5%
10/29/202416.1%-7.6%-2.6%
8/6/20246.2%8.1%16.6%
4/30/20245.7%5.6%0.3%
2/22/2024-4.7%0.8%1.7%
10/31/202319.4%26.5%49.2%
8/1/2023-3.9%-5.3%-1.1%
5/2/20232.4%10.0%5.6%
2/21/2023-11.1%-9.2%-10.7%
11/1/202214.0%9.8%14.9%
8/2/202212.6%9.7%-10.3%
5/3/2022-17.6%-25.6%-5.1%
2/28/20225.4%6.1%34.4%
11/9/2021-0.9%-3.7%-7.0%
8/11/20214.1%3.4%18.9%
5/11/2021-3.1%11.5%22.3%
3/25/20213.5%14.9%-2.1%
11/12/2020-7.4%-9.8%-12.0%
SUMMARY STATS   
# Positive141413
# Negative9910
Median Positive5.9%9.1%16.6%
Median Negative-4.1%-5.9%-4.3%
Max Positive19.4%26.5%49.2%
Max Negative-17.6%-25.6%-12.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202410/29/202410-Q
06/30/202408/06/202410-Q
03/31/202404/30/202410-Q
12/31/202302/22/202410-K
09/30/202310/31/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/21/202310-K
09/30/202211/01/202210-Q
06/30/202208/02/202210-Q
 Collapse to Preview
Report DateFiling DateFiling
03/31/202605/07/202610-Q
12/31/202502/24/202610-K
09/30/202511/04/202510-Q
06/30/202508/05/202510-Q
03/31/202505/06/202510-Q
12/31/202402/25/202510-K
09/30/202410/29/202410-Q
06/30/202408/06/202410-Q
03/31/202404/30/202410-Q
12/31/202302/22/202410-K
09/30/202310/31/202310-Q
06/30/202308/01/202310-Q
03/31/202305/02/202310-Q
12/31/202202/21/202310-K
09/30/202211/01/202210-Q
06/30/202208/02/202210-Q
03/31/202205/03/202210-Q
12/31/202102/28/202210-K
09/30/202111/09/202110-Q
06/30/202108/10/202110-Q
03/31/202105/11/202110-Q
12/31/202003/25/202110-K
09/30/202011/12/202010-Q
06/30/202008/20/2020424B4
03/31/202007/27/2020S-1

Recent Forward Guidance

Updated 6/1/2026

Latest: Q1 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.00 Bil1.02 Bil1.04 Bil0 AffirmedGuidance: 1.02 Bil for 2026

Prior: Q4 2025 Earnings Reported 2/24/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.00 Bil1.02 Bil1.04 Bil19.3% Higher NewGuidance: 855.00 Mil for 2025

Insider Activity

Updated 5/18/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell128202637.153,746139,171911,004Form
2Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell120202635.9220,961  Form
3Dayno, Jeffrey MPRESIDENT, CEODirectSell1217202540.1125,933  Form
4Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1209202539.5420,000  Form
5Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1125202535.003,427  Form
 Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell128202637.153,746139,171911,004Form
2Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell120202635.9220,961  Form
3Dayno, Jeffrey MPRESIDENT, CEODirectSell1217202540.1125,933  Form
4Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1209202539.5420,000  Form
5Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell1125202535.003,427  Form
6Kapadia, SandipCHIEF FINANCIAL OFFICERDirectSell819202536.5021,573  Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/4/2026